Literature DB >> 31398438

Preparation of H1N1 microneedles by a low-temperature process without a stabilizer.

Hye-Rin Jeong1, Sehee Park2, Jee-Hyun Park1, Joon-Yong Bae2, Ga-Yeong Kim2, Seung-Ki Baek3, Man-Seong Park4, Jung-Hwan Park5.   

Abstract

During the manufacture of H1N1 microneedles, a stabilizer is usually added to maintain the antigenicity of the vaccine. However, finding a suitable stabilizer is difficult, and the addition of a stabilizer can limit the antigen dose and the addition of an adjuvant because of the limited volume of the microneedles. In this study, the authors evaluated whether H1N1 microneedles could be fabricated without a stabilizer by keeping the production environment at a low temperature. H1N1 microneedle patches without a stabilizer were prepared in a process that involved maintaining a low temperature of 10 °C. The protective immune response to this method of drug application was investigated by comparing it with traditional intramuscular (IM) immunization and with the use of H1N1 microneedles with a stabilizer. A process-sensitive antigen, H1N1, was stabilized without the use of a stabilizer in a process that maintained a low temperature of 10 °C. The preparation process consisted of coating and drying processes. In animal experiments, mice were immunized using an array of low-temperature H1N1 microneedles without a stabilizer (LT-MN), and they showed strong antibody responses. Compared to three other application methods of traditional IM immunization, low-temperature H1N1 microneedles with a stabilizer (LT-MN-T), and room-temperature H1N1 microneedles with a stabilizer (RT-MN-T), LT-MN produced comparable results in inducing protective immunity. A plaque reduction neutralization test found that LT-MN and LT-MN-T provided greater immunity compared with IM and RT-MN-T. A process in which the temperature is maintained at 10 °C can provide successful vaccination with H1N1 microneedles without the addition of a stabilizer. This process can be applied to various temperature-sensitive biologics.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  H1N1; Influenza; Low-temperature process; Microneedles; Stabilizer; Temperature-sensitive

Mesh:

Substances:

Year:  2019        PMID: 31398438     DOI: 10.1016/j.ejpb.2019.08.005

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  5 in total

1.  Development of the H3N2 influenza microneedle vaccine for cross-protection against antigenic variants.

Authors:  Yura Shin; Jeonghun Kim; Jong Hyeon Seok; Heedo Park; Hye-Ran Cha; Si Hwan Ko; Jae Myun Lee; Man-Seong Park; Jung-Hwan Park
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

Review 2.  How physical techniques improve the transdermal permeation of therapeutics: A review.

Authors:  Yan Gao; Lina Du; Qian Li; Qi Li; Lin Zhu; Meiyan Yang; Xiu Wang; Bonian Zhao; Shan Ma
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

3.  Progress in microneedle array patch (MAP) for vaccine delivery.

Authors:  Thuy Trang Nguyen; Yujeong Oh; Yunseo Kim; Yura Shin; Seung-Ki Baek; Jung-Hwan Park
Journal:  Hum Vaccin Immunother       Date:  2020-07-15       Impact factor: 3.452

Review 4.  Microarray patches enable the development of skin-targeted vaccines against COVID-19.

Authors:  Emrullah Korkmaz; Stephen C Balmert; Tina L Sumpter; Cara Donahue Carey; Geza Erdos; Louis D Falo
Journal:  Adv Drug Deliv Rev       Date:  2021-02-02       Impact factor: 17.873

5.  Evaluation of efficacy and safety of intradermal delivery of vaccines through microneedle(s) in human beings: a protocol for a systematic review.

Authors:  Ishumeet Kaur Bajwa; Navneet Kaur; Jeanne M Dsouza; Joseph L Mathew
Journal:  Syst Rev       Date:  2022-08-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.